Theriva Biologics (TOVX) Receivables - Net (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Receivables - Net of $1.7 million for Q1 2026, up 6.87% year-over-year from $1.6 million in Q1 2025, and down 49.39% quarter-over-quarter from $3.4 million in Q4 2025.
Theriva Biologics (TOVX) Receivables - Net (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Receivables - Net for 9 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 6.87% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 6.87% YoY), while the FY2025 annual figure was $3.4 million, up 3.81% from the prior year.
- Receivables - Net eased to $1.7 million in Q1 2026 per TOVX's latest filing, from $3.4 million in the prior quarter.
- Across five years, Receivables - Net topped out at $3.4 million in Q4 2025 and bottomed at $1.4 million in Q3 2023.
- Historically, Receivables - Net has averaged $2.0 million across 4 years, with a median of $1.8 million in 2024.
- Annual changes were most pronounced in 2024 — Receivables - Net soared 78.15% — and 2025, when it retreated 10.44%.
- Theriva Biologics' Receivables - Net stood at $1.8 million in 2023, then jumped by 78.15% to $3.2 million in 2024, then rose by 3.81% to $3.4 million in 2025, then tumbled by 49.39% to $1.7 million in 2026.
- Business Quant data shows TOVX's Receivables - Net at $1.7 million in Q1 2026, $3.4 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.68 Mn |
| Jun 30, 2026 | 1.68 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1.70 Mn |
| Dec 31, 2025 | 3.35 Mn |
| Dec 31, 2025 | 3.35 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.72 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | 3.23 Mn |
| Dec 31, 2024 | 3.23 Mn |
| Sep 30, 2024 | 1.83 Mn |
| Sep 30, 2024 | 1.83 Mn |
| Jun 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.77 Mn |
| Mar 31, 2024 | 1.77 Mn |